Purpose: Renal disease is common among people living with human immunodeficiency virus (HIV). However, there is limited information on the incidence and risk factors associated with renal dysfunction among this population in Asia.
values ≤60 mL/min/1.73 m 2 taken ≥3 months apart. Generalized estimating equations were used to identify factors associated with eGFR change. Competing risk regression adjusted for study site, age and sex, and cumulative incidence plots were used to evaluate factors associated with chronic kidney disease (CKD).
Results: Of 2547 patients eligible for this analysis, tenofovir was being used by 703 (27.6%) at baseline. Tenofovir use, high baseline eGFR, advanced HIV disease stage, and low nadir CD4 were associated with a decrease in eGFR during follow-up.
Chronic kidney disease occurred at a rate of 3.4 per 1000 patient/years. Factors associated with CKD were tenofovir use, old age, low baseline eGFR, low nadir CD4, and protease inhibitor use.
Conclusions:
There is an urgent need to enhance renal monitoring and management capacity among at-risk groups in Asia and improve access to less nephrotoxic antiretrovirals. Tenofovir is widely used as one component of a nucleoside backbone in ART and has been recommended by the World Health Organization. Tenofovir has been associated with renal toxicity ranging from Fanconi's syndrome, acute kidney injury (AKI), and reduction in estimated glomerular filtration rate (eGFR), sometimes progressing to CKD. [3] [4] [5] [6] There is limited information on the incidence and risk factors associated with renal dysfunction among PLHIV in Asia. We previously reported an incidence of TDF-associated renal dysfunction of 1.75 per 100 years in the TREAT Asia HIV Observational Database (TAHOD) cohort. 6 However, we did not compare renal dysfunction among PLHIV using TDF and other non-TDF-based regimens. In this analysis, we describe the long-term changes in eGFR among patients using TDF and non-TDF-based ART and report the incidence and risk factors associated with CKD among patients on ART in our regional cohort.
2 | METHODS
| Patient selection and baseline data
The study population consisted of HIV-infected patients enrolled in TAHOD before 30 September 2016. This cohort contributes to the International Epidemiology Databases to Evaluate AIDS global consortium and has been previously described. 7 Recruitment started in 2003.
In September 2016, TAHOD included data from 8984 adults (≥18 years of age) that had ever received care from one of 20 clinics in Cambodia (n = 1), China (n = 1), Hong Kong (n = 1), India (n = 2), Indonesia (n = 2), Japan (n = 1), Malaysia (n = 2), Philippines (n = 1), Singapore (n = 1), South Korea (n = 1), Taiwan (n = 1), Thailand (n = 4), or Vietnam (n = 2). These sites are predominantly public or universitybased HIV referral clinics. Ethics approval was obtained at the sites, TREAT Asia/amfAR (coordinating centre), and the Kirby Institute (data management and statistical analysis centre). Patient consent is deferred to the individual participating sites and their institutional review boards.
Individuals were included in this analysis if they started ART during or after 2003, had a serum creatinine measurement at ART initiation (baseline), and had at least 2 follow-up creatinine measurements that were taken ≥3 months apart. The window period for baseline creatinine was between 3 months before ART initiation to 1.5 months after ART initiation. Values observed closest to ART initiation were used. ART was defined as a regimen containing ≥3 antiretroviral drugs. Estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 8 Patients with a baseline eGFR ≤60 mL/min/1.73 m 2 were excluded.
Chronic kidney disease was defined as 2 consecutive eGFR measurements ≤60 mL/min/1.73 m 2 taken ≥3 months apart. 
| Statistical analysis
Follow-up was censored at (1) the time of TDF cessation for individuals using TDF at ART initiation, (2) the time of TDF initiation for those not using TDF at ART initiation, or (3) the last recorded clinic visit while still eligible for inclusion "(including the date 12 months after the final clinic visit for those lost to follow-up, the date of death, or the date of CKD diagnosis [for the change in eGFR analysis only]).
The Kruskal-Wallis test was used to compare time on ART and rates of creatinine monitoring among TDF and non-TDF users.
| eGFR analysis
Generalized estimating equations adjusted for study site were used to identify factors associated with change in eGFR. Follow-up in this analysis was additionally censored at the time of CKD onset. Creatinine measurements taken after baseline were evaluated at 3 (±1. 
| CKD analysis
Competing risk regression adjusted for study site, age and sex, and Covariates were considered for inclusion in our final models if one or more categories exhibited a univariate P-value < . 
| Changes in eGFR over time

| Chronic kidney disease
Overall, 37 cases of CKD occurred over 10 900.5 years of follow-up at a rate of 3.4 (95% CI 2.5-4.7) events per 1000 patient/years (see Figure 2 ).
Factors associated with CKD are shown in Table 2 . Loss to follow-up occurred in 128 patients at a rate of 11.7 (95% CI 9.9-14.0) events per
KEY POINTS
• Currently, TDF is a recommended component of the nucleoside backbone.
• This study documents a significant risk of decline in eGFR and development of CKD on a TDF-based regimen across PLHIV in Asia.
• The incidence of CKD in our cohort is (3.4 per 1000
person-years).
• There is an urgent need to build up renal monitoring and management capacities across Asia and improve access to less nephrotoxic ARVs like TAF.
[95% CI 8. high with TDF, ATV/r, and LPV/r, and this risk increased with each year of exposure to these ARVs. 12 The overall incidence of CKD in the above cohort was 1.76 per 1000 person-years of follow-up.
The incidence of CKD in our cohort (3.4 per 1000 person years) is substantially higher than that reported in the DAD cohort although we also included patients with baseline eGFR of 60 to 90/mL/min/ 1.73 m 2 in our analysis. However, another DAD study with comparable inclusion criteria demonstrated a higher rate of CKD viz 10.5
per 1000 person-years 13 . Few other studies have also documented higher incidence of CKD among PLHIV 14,15 . 
Numerous reports have documented higher incidence of CKD in Asian PLHIV compared with European and US cohorts. In a study from India, PLHIV on a TDF-based regimen had higher and faster decline in the eGFR compared with PLHIV in the United Kingdom. 16 In a 12-year observational cohort in Tokyo, incidence of CKD was 20.6 per 1000 years of follow-up and was strongly associated with use of TDF. 4 Chronic kidney disease has been reported among 7.3% of Vietnamese PLHIV on ART. 17 Apart from TDF use, other risk factors including low body weight, age, male sex, duration of ART, and concomitant comorbidities, such as hypertension, were strongly associated with CKD in these studies. Interestingly, in our study, we found lower baseline eGFR, nadir CD4 counts, uncontrolled viremia, and current PI/r use associated with incident CKD. Although we did not have adequate power to determine which PI/r was associated with CKD, previous analyses have indicated that ATV causes nephrolithiasis and is associated with development of interstitial nephritis, 18, 19 switching from ATV/r or LPV/r to DRV/r is associated with improvement in kidney function, 20 and use of a concomitant PI/ r with TDF amplifies the renal toxicity of the later due to inhibition of Multi-resistant Protein 4 (MRP-4) efflux channels in the proximal tubular cells by ritonavir leading to TDF accumulation in the cells. 21 Nadir CD4 counts were significantly associated with CKD, suggesting that initiating ART early may help in reducing this risk. For example, early initiation of ART in the Strategic Timing for Antiretroviral Therapy (START) study was associated with a modestly higher eGFR and lower risk of proteinuria. 22 In addition, TDF use may be best avoided among patients with lower baseline eGFR as is recommended by some guidelines. 23 Estimated GFR can be affected by ethnicity and body composition. We used the CKD-EPI equation to estimate eGFR in our cohort.
In a Thai cohort, reexpressed MDRD formula with Thai racial correction factor was most accurate in estimating GFR. 24 However, in the absence of any gold standard, CKD-EPI has been used to estimate GFR reasonably precisely in most studies across diverse ethnicities. 25, 26 Currently, TDF is a recommended component of the nucleoside backbone in the 2016 World Health Organization Consolidated ARV guidelines. As TDF use is scaled up in Asia, significant numbers of PLHIV may develop renal toxicity, decline in eGFR, or progress to CKD. Recovery from the decline in eGFR after TDF discontinuation is slow and irreversible among a third of PLHIV. 27 As such, it is especially important that monitoring for renal toxicity is urgently Our study has several limitations. We did not use other markers for defining CKD, including proteinuria and radiologic evidence, as these data were not uniformly collected across sites. Including these would, however, have been likely to increase the documented incidence of CKD in the study population. We also do not have access to determine true GFR in routine clinic settings across Asia as there may be substantial difference between measured calculated eGFR.
Because of the small number of patients with documented diabetes, we did not include diabetes as a covariate. Key strengths of this analysis include a large heterogeneous PLHIV study population (largest study of CKD among PLHIV from Asia to date) and robust statistical methods.
| CONCLUSION
Compared with other studies, we observed a low prevalence of CKD in this cohort of Asian individuals; however, progression to CKD was substantially associated with exposure to TDF. There is an urgent need to build up renal monitoring and management capacities across Asia and improve access to less nephrotoxic ARVs like TAF.
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